Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of CR-001 in advanced or metastatic solid tumors
2025-523590-42-00Phase 2Authorised
- Sponsor
- Crescent Biopharma
- Start
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, open-label trial of CR-001 in Nonhematologic neoplasms, hepatocellular carcinoma (HCC), biliary cancer and 7 more (3 arms), sponsored by Crescent Biopharma. Primary endpoints: Dose-limiting toxicities and maximum tolerated dose, Treatment-emergent adverse events and serious adverse events and 1 more. Planned start Jun 2026; status: authorised.
02
Drugs
CR-001
03
Conditions
Nonhematologic neoplasmshepatocellular carcinoma (HCC)biliary cancerendometrial cancer (EC)Cervical Cancer (CC)
Beyond the preview
Go deeper on 2025-523590-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523590-42-00.